Ionis reports fourth quarter and full year 2024 financial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
February 20, 2025 5:50 AM ESTRaymond James analyst Gary Nachman lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $61.00) while maintaining a Strong Buy rating.
The analyst comments "Key Updates. 1) Wainua in ATTR-PN. AZN booked $42M in 4Q (+83% q/q; FY $86M), with ~$10M royalties to IONS (FY $20M). U.S. launch is progressing well with new-to-brand share ~40%; seeing good... More
